Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT07314801
Enrolling by invitation Observational

FINancial Toxicity and CAncer REcovery in YOUNG Adults

NCT07314801 · tracked via the Priya Life Science Germany tracker
Sponsor
University Medical Center Goettingen
Phase
Observational
Started
2025-12
Last updated
2026-01-02

Condition(s) studied

Financial Toxicity Related to Cancer Diagnosis and Tretment in Adolescents and Young Adults

Study summary

The FINCARE-Young study aims to investigate the extent and development of financial toxicity in adolescents and young adults with cancer. The primary purpose of this study is to assess the level of financial burden experienced during the acute phase of cancer treatment and after completion of therapy, and to analyze changes over time. In addition, the study seeks to identify sociodemographic, clinical, and socioeconomic factors associated with financial toxicity, as well as its impact on employment and social reintegration. By focusing on young adult cancer survivors, this study addresses an underexplored population and seeks to generate evidence to improve supportive care strategies and reduce long-term financial consequences of cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18 to 39 years at the time of initial cancer diagnosis * Diagnosis of a malignant neoplasm * Receipt of oncological treatment at the University Medical Center Göttingen * Completion of primary cancer therapy at the time of study participation * Initial diagnosis between 2014 and 2024 * Ability to provide informed consent * Sufficient German language skills to participate in a telephone interview and complete questionnaires Exclusion Criteria: * Age below 18 years or above 39 years at the time of initial cancer diagnosis * No history of malignant disease * Ongoing primary cancer treatment at the time of study participation * Severe cognitive impairment or psychiatric condition preventing reliable participation * Insufficient German language proficiency to complete interviews or questionnaires * Withdrawal of informed consent

Primary outcome measure(s)

  • Financial toxicity — From the acute phase of cancer treatment to the time of study participation after completion of therapy (retrospective assessment of treatment period and current assessment at follow-up), assessed only at one time point at study enrollment.
    Financial toxicity, assessed using the Comprehensive Score for Financial Toxicity (COST) questionnaire, measured during the acute phase of cancer treatment and at the time of study participation, including change over time.

Trial sites (1)

FacilityCityRegionStatus
University Medicine Göttingen Göttingen Lower Saxony

More University Medical Center Goettingen trials in Germany

Prospective Exploratory Cohort Study on Ganglion Cell Degeneration in Retinitis Pigmentosa Patients Enrolling by invitation
Improving Dental Care for Patients With Head and Neck Tumors Recruiting
TREMOR IN CHARCOT-MARIE-TOOTH Recruiting
A Multi-omic Approach to the Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease (CMT1A) Recruiting
Orofacial Pain and Oral Health-Related Quality of Life in Musicians in German Amateur Orchestras Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07314801 on ClinicalTrials.gov ↗ ← All trials in Germany